PARP inhibitors such as olaparib and talazoparib have been approved for unresectable/recurrent breast cancer with germline BRCA1 or BRCA2 (BRCA1/2) mutations and without HER2 expression. This evidence concerns the gene BRCA2 and breast carcinoma.